ArticleInternational journal of clinical oncology2026
Risk factors for shorter recurrence-free survival in patients with resected biliary tract cancer treated with adjuvant S-1 chemotherapy.
Article in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdjuvant S-1 chemotherapy (ASC) has become the standard postoperative treatment for biliary tract cancer (BTC) in Japan following publication of the results of the ASCOT study, a recent nationwide randomized controlled study. However, recurrence remains common, and risk factors specific to patients treated with ASC are unclear.
methodsWe retrospectively investigated the data of 56 patients with resected BTC at our institution between August 2021 and October 2023. Recurrence-free survival (RFS), overall survival (OS), and treatment safety were evaluated. Cox proportional hazards regression analysis was performed to identify the risk factors for shorter RFS.
resultsOver a median follow-up of 22.6 months, 15 patients (26.8%) developed recurrence. The 12- and 24-month RFS rates were 84.8% and 71.6%, respectively, and the 12- and 24-month OS rates were 92.4% and 85.7%, respectively. Both univariate and multivariate analyses identified poorly differentiated tumor histology as a significant risk factor for shorter RFS. In addition, univariate analysis, but not multivariate analysis, also identified elevated pre-ASC serum CA19-9 levels (≥ 37 U/mL) as a significant risk factor for shorter RFS. Adverse events of ≥ grade 3 occurred in 3.6% of patients receiving ASC.
conclusionsPoorly differentiated tumor histology may be a risk factor for shorter RFS in patients with resected BTC treated with ASC.
Indexed as
Identifiers
42842179What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.